Metabolic risk factors, drugs, and obesity [6]

New England Journal of Medicine

Volumn 354, Issue 9, 2006, Pages 974-975

  Padwal, Raj ^a   Majumdar, Sumit ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT; TRIACYLGLYCEROL;

BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET; DRUG APPROVAL; DRUG MARKETING; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HUMAN; LETTER; MORBIDITY; MORTALITY; OBESITY; PRIORITY JOURNAL; RANDOMIZATION; RISK FACTOR; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; HUMANS; OBESITY; OVERWEIGHT; PIPERIDINES; PYRAZOLES; WEIGHT LOSS;

EID: 33644601061     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMc053448     Document Type: Letter

References (5)

1. Després J-P, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
2. Boyd ST, Fremming BA. Rimonabant - a selective CB1 antagonist. Ann Pharmacother 2005;39:684-90.
3. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6.
4. Haslam DW, James WPT. Obesity. Lancet 2005;366:1197-209.
5. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003;4:CD004094.